PDS Biotechnology (PDSB) Expected to Announce Quarterly Earnings on Wednesday

PDS Biotechnology (NASDAQ:PDSB) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, March 26th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.

PDS Biotechnology Price Performance

Shares of NASDAQ:PDSB opened at $1.39 on Wednesday. The firm has a market cap of $53.09 million, a PE ratio of -1.20 and a beta of 1.68. The firm’s fifty day moving average is $1.43 and its 200-day moving average is $2.24. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84. PDS Biotechnology has a 52 week low of $1.13 and a 52 week high of $5.00.

Wall Street Analysts Forecast Growth

PDSB has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of PDS Biotechnology in a report on Thursday, March 13th. B. Riley dropped their target price on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, November 25th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.67.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.